Open Access

Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β

  • Authors:
    • Xuyun Gu
    • Chen Wei
    • Xishan Zhu
    • Feiping Lu
    • Bo Sheng
    • Xuefeng Zang
  • View Affiliations

  • Published online on: May 17, 2018     https://doi.org/10.3892/etm.2018.6181
  • Pages: 171-177
  • Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sepsis with severe systemic inflammation remains a great challenge for the intensive care unit in clinics. Although biomarkers have been identified to diagnose, monitor and predict these syndromes, novel therapeutic approaches are required for the amelioration of symptoms of sepsis and septic shock. The present study demonstrated that interleukin (IL)‑31 was able reduce the mortality rate of lipopolysaccharide (LPS)‑induced sepsis with the reduction of inflammatory cytokines in the sera. IL‑31 also inhibited IL‑1β production in the peritoneal lavage fluid in LPS‑induced or cecal ligation and puncture‑induced sepsis. The in vitro mechanism responsible for IL‑31 regulation on peritoneal IL‑1β activation following LPS challenge was explored. It was demonstrated that IL‑1β secretion was suppressed by IL‑31 treatment from LPS‑challenged peritoneal macrophages following adenosine triphosphate stimulation, which is an activator of NLR family, pyrin domain‑containing 3 (NLRP3). Furthermore, IL‑31 inhibited the expression of NLRP3 at the transcriptional level. In human THP‑1 cells, anti‑IL‑31/anti‑IL‑31 receptor (R) neutralizing antibody enhanced NLRP3 expression as well as IL‑1β activation, suggesting a role of the IL‑31‑IL‑31R‑NLRP3‑IL‑1β signaling axis in the physiological status of sepsis. On the other hand, IL‑31 displayed a negative effect on the NLRP1 inflammasome, but not on NLRP3 on the LPS‑primed human peripheral blood monocytes, resulting in reduction of the inflammatory cytokine, tumor necrosis factor (TNF)‑α, in the supernatant. Taken together, the present data implied that T helper 2‑type cytokine, IL‑31, may be a promising therapeutic option for treatment of sepsis and septic shock in clinics.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gu X, Wei C, Zhu X, Lu F, Sheng B and Zang X: Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β. Exp Ther Med 16: 171-177, 2018
APA
Gu, X., Wei, C., Zhu, X., Lu, F., Sheng, B., & Zang, X. (2018). Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β. Experimental and Therapeutic Medicine, 16, 171-177. https://doi.org/10.3892/etm.2018.6181
MLA
Gu, X., Wei, C., Zhu, X., Lu, F., Sheng, B., Zang, X."Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β". Experimental and Therapeutic Medicine 16.1 (2018): 171-177.
Chicago
Gu, X., Wei, C., Zhu, X., Lu, F., Sheng, B., Zang, X."Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β". Experimental and Therapeutic Medicine 16, no. 1 (2018): 171-177. https://doi.org/10.3892/etm.2018.6181